MedPath

Study to Assess Safety and Efficacy of DF01 in Reducing Prolonged Labor

Phase 2
Completed
Conditions
Pregnancy
Labor
Interventions
Drug: Placebo
Registration Number
NCT00710242
Lead Sponsor
Dilafor AB
Brief Summary

The study is a Proof-of-concept study to evaluate if DF01 can prevent protracted labor. Time to delivery will be measured from the time of at least 3 cm cervix dilatation and 3 contractions of minimum one minute's duration/10 minutes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
263
Inclusion Criteria
  • healthy nulliparous females
  • normal singleton pregnancy
  • intact membranes
Exclusion Criteria
  • breech or other abnormal presentation
  • intercurrent illness
  • pregnancy complications
  • vaginal bleeding in third trimester
  • etc

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1DF01DF01
2Placebo-
Primary Outcome Measures
NameTimeMethod
Time from the time of at least 3 cm cervix dilatation and 3 contractions of minimum one minute's duration/10 minutes until partus in women with vaginal deliverySee above
Secondary Outcome Measures
NameTimeMethod
Complications of laborAt delivery

Trial Locations

Locations (15)

Lanssjukhuset

🇸🇪

Kalmar, Sweden

Kvinnokliniken Alvsborgs sjukhus Boras

🇸🇪

Boras, Sweden

Lanssjukhuset Ryhov

🇸🇪

Jonkoping, Sweden

Kärnsjukhuset

🇸🇪

Skövde, Sweden

Sodersjukhuset

🇸🇪

Stockholm, Sweden

Sahlgrenska/Ostra sjukhuset

🇸🇪

Goteborg, Sweden

Karolinska Universistetssjuhuset

🇸🇪

Huddinge, Sweden

Universitetssjukhuset

🇸🇪

Örebro, Sweden

Vrinnevisjukhuset

🇸🇪

Norrköping, Sweden

Nyköpings lasarett

🇸🇪

Nyköping, Sweden

Danderyds sjukhus

🇸🇪

Stockholm, Sweden

Norra Älvsborgs länssjukhus

🇸🇪

Trollhättan, Sweden

Akademiska sjukhuset

🇸🇪

Uppsala, Sweden

Centrallasarettet

🇸🇪

Växjö, Sweden

Gavle sjukhus

🇸🇪

Gavle, Sweden

© Copyright 2025. All Rights Reserved by MedPath